Cardiac Toxicity in Medical Treatment of Breast Cancer

Cardiac Toxicity in Medical Treatment of Breast Cancer

This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.

In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.

Inclusion Criteria:

• Diagnosis of HER2 positive breast cancer
• Adjuvant treatment with trastuzumab

Exclusion Criteria:

• Left ventricle ejection fraction (LVEF) <50%
• Chronic or persistent atrial fibrillation
• History of moderate or severe valvular heart disease.